Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno Report issue

Academic/Hospital Phase 3 Phase 4

Organization Overview

First Clinical Trial
2017
NCT04627337
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Ariel Dogliotti | Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno | Instituto Milstein-CONICET

Active Ingredients

Drugs in Phase 4 Trials (2)

carrageenan (1 trial)

saccharomyces boulardii (1 trial)

Drugs in Phase 3 Trials (3)

arvac-cg (1 trial)

COVID-19 convalescent plasma (2 trials)

dexamethasone (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Lung Injury (Phase 3)

Irritable Bowel Syndrome (Phase 4)

Pneumonia (Phase 3)

Respiratory Distress Syndrome (Phase 3)

Respiratory Distress Syndrome, Newborn (Phase 3)

Syndrome (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 6
  • # of Trial APIs: 5